



BillionToOne Celebrates Major Milestone: 1 Million UNITY Tests

March 18, 2025

UNITY is the only commercially available non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a single maternal blood draw.

MENLO PARK, Calif., March 18, 2025 /PRNewswire/ -- [BillionToOne, Inc.](#), a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, has reached a significant milestone of conducting one million [UNITY](#) prenatal tests. This achievement highlights the company's exceptional execution and superior product differentiation, which has fueled remarkable year-over-year growth and established BillionToOne as a leading player in the U.S. prenatal testing market.

Powered by BillionToOne's patented Quantitative Counting Template™ (QCT™) molecular counting technology, the UNITY Fetal Risk Screen™ stands apart as the only prenatal genetic test that directly assesses a baby's risk for recessively inherited conditions, including cystic fibrosis, spinal muscular atrophy (SMA), and sickle cell disease, without requiring a male partner's sample or invasive testing.

"Surpassing 1 million UNITY tests in only 5 years is not just a milestone for our company, but a testament to how our technology is transforming prenatal care," said Oguzhan Atay, Ph.D., Co-Founder and CEO of BillionToOne. "What is more impressive is that our annual run-rate is already above 500,000 UNITY tests this year, indicating truly exponential growth and establishment of UNITY as the next standard in prenatal care. This achievement would not be possible without the dedication of our employees, the support of our partners, and the trust of our healthcare providers."

BillionToOne has firmly established itself as the fastest-growing molecular diagnostics laboratory, with 100% year-over-year revenue growth in 2024.

This milestone further solidifies BillionToOne's position as a leading provider in democratizing

access to essential prenatal testing, particularly for those who need it most. BillionToOne's QCT technology is also an integral part of the company's Northstar Select[®] and Northstar Response[®] assays, designed for therapy selection and treatment response monitoring. These assays are transforming cancer care by bringing the precision of single-molecule sensitivity and quantification into treatment selection and response monitoring through a simple, non-invasive blood test.

For more information about UNITY, visit www.unityscreen.com.

About BillionToOne

Headquartered in Menlo Park, California, BillionToOne is a precision diagnostics company on a mission to make molecular diagnostics more accurate, efficient, and accessible for all. The company's patented Quantitative Counting Templates[™] (QCT[™]) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level as early as 9 weeks gestation. For more information, please visit www.billiontoone.com.

Media Contact: billiontoone@moxiegrouppr.com

SOURCE BillionToOne